Becton, Dickinson and Company (BDX)

Market Cap	66.25B
Revenue (ttm)	19.72B
Net Income (ttm)	1.32B
Shares Out	289.01M
EPS (ttm)	4.51
PE Ratio	50.83
Forward PE	16.53
Dividend	$3.80 (1.66%)
Ex-Dividend Date	Jun 10, 2024

Volume	640,293
Open	229.06
Previous Close	229.27
Day's Range	227.65 - 231.14
52-Week Range	224.00 - 287.32
Beta	0.46
Analysts	Buy
Price Target	286.71 (+25.07%)
Earnings Date	Aug 1, 2024

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascula...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 23, 1962
• Employees: 73,000
• Stock Exchange: NYSE
• Ticker Symbol: BDX

Financial Performance

In 2023, BDX's revenue was $19.37 billion, an increase of 2.66% compared to the previous year's $18.87 billion. Earnings were $1.42 billion, a decrease of -15.69%.

Analyst Forecast

According to 7 analysts, the average rating for BDX stock is "Buy." The 12-month stock price forecast is $286.71, which is an increase of 25.07% from the latest price.

Price Target

$286.71

(25.07% upside)

Analyst Consensus: Buy